NCT01940445已完成不适用
Impact of Synergistic Sequential Treatment (SST) of Fractional Non-ablative and Q-Switched Lasers on Skin Texture
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Improvement
研究概览
简要总结
At least thirty (30) subjects, Fitzpatrick-Goldman Skin Type II-V will be enrolled in 2 clinical sites; each clinic will enroll at least 15 subjects.
Subjects should present visible wrinkles and/or elastosis requiring treatment.
Hypothesis: The SST will improve the appearance of the wrinkles/elastosis as well as general skin tone by at least 25% as compared to M22 ResurFX 1565nm module alone, for at least 75% of the subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to read, understand and provide written Informed Consent;
- •Healthy adult, male or female, 30-65 years of age with Fitzpatrick-Goldman skin type II-V;
- •Having suitable facial areas with wrinkles Fitzpatrick-Goldman Wrinkle and Elastosis Score of 3-6 to be treated;
- •Able and willing to comply with the treatment/follow-up schedule and requirements;
- •Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nova ring, partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.
排除标准
- •Skin type I, VI
- •Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding
- •History of post inflammatory hyperpigmentation
- •Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study
- •Use of photosensitive medication for which light exposure is contraindicated.
- •Use of oral isotretinoin (Accutane®) within 3 months of initial treatment or during the course of the study. Note: skin must regain its normal degree of moisture prior to treatment.
- •Having indurate acne, varicella scars, or severe open wound stages of rosacea.
- •Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in treated area
- •Prior treatment, such as chemical peel (especially phenol based) or dermabrasion, in treated area within 3 months of initial treatment or during the course of the study;
- •Prior skin laser/light or another device treatment in treated area within 6 months of initial treatment or during the course of the study
- •Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants
- •Prior use of Botox in treatment area within 6 months
- •Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study
- •Any other surgery in treated area within 9 months of initial treatment or during the course of the study.
- •Participation in a study of another investigational device or drug involving the same anatomical site within 3 months prior to enrollment or during this evaluation, or if not involving the same anatomical site, as per the Investigator's discretion
- •History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
- •Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma)
- •Concurrent inflammatory skin conditions, including, but not limited to, severe rosacea
- •Open laceration or abrasion of any sort on area to be treated during the course of treatment
- •Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;
- •Multiple dysplastic nevi in area to be treated
- •Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to treatment (as per the subject's physician discretion)
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
- •Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer on the face.
- •Pigmented lesion in the treated area that appears cancerous, pre-cancerous or is not deemed suitable for photo therapy, as determined by a dermatologist.
- •Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process; Participation in a study of another device or drug within 3 month prior to study enrollment or during this study, and as per the Investigator's discretion, as long as not contradictory to any of the above criteria
- •Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
- •Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study.
- •For subjects undergoing test spots: considerable undesired response consisting of skin hypopigmentation (long term whitening), a scar or pre scar formation, or any response deemed by the Investigator as grounds for exclusion.
- •Allergies to anesthetics.
结局指标
主要结局
Improvement
时间窗: 3 months following 3rd treatment
Investigator subjective evaluation of the extent of wrinkles/elastosis as well as general skin tone improvement of each side of the face at the 3 month follow-up visit as assessed by Fitzpatrick-Goldman Wrinkle Class / Elastosis Score classification and by percentage category scales
次要结局
- Downtime(Following treatment- baseline, 4, 8 weeks)
- Comfort(Following treatment- baseline, 4, 8 weeks)
- Biopsies(Immediately post 1st treatment or at 1, 3 or 6 month post last treatment)
- Improvement(1 and 6 months following 3rd treatment)
- Blinded improvement(1 year following study initiation)
- Skin response(Following treatments- Baseline, 4, 8 weeks)
- Improvement by subject(1, 3 and 6 months follow up)
- Adverse Events(Following treatment #1, 2 and 3 and all follow up visits)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Impact of M22 Synergistic Sequential Treatment (SST)Improvement of Wrinkles/Elastosis and/or PigmentationNCT02032771Lumenis Be Ltd.33
已完成
不适用
The assessment of synergistic effect of STFX and a-PDT to MRONJJPRN-UMIN000027257agasaki University12
招募中
3 期
Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of CareIschemic StrokeNCT06660719Shin Poong Pharmaceutical Co. Ltd.852
Unknown
不适用
Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir TherapyChronic Hepatitis BNCT02589652Huashan Hospital294
已完成
2 期
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPAIschemic StrokeNCT04479449Shin Poong Pharmaceutical Co. Ltd.178